Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06919328 · ClinicalTrials.gov registry record · NA
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
A NA study of Healthy Aging, sponsored by Nutraceuticals Research Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06919328: Recruiting NA study of Healthy Aging, sponsored by Nutraceuticals Research Institute.
NCT06919328 is a NA study of Healthy Aging that is actively recruiting participants, run by Nutraceuticals Research Institute. The registered enrollment target is 70 participants, below the 120-participant average among 40 other Healthy Aging trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06919328, a NA study of Healthy Aging, is actively recruiting participants, sponsored by Nutraceuticals Research Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the subjective effects of injection administration of NR on healthy adult populations.
Primary Outcome
The MPQ contains 78 pain related terms to identify the quantity and type of pain experienced. This multi-dimensional tool has three components; sensory, cognitive, emotional. Higher scores indicate higher levels of pain.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Niagen®
- OTHER NAD+
Study Locations (1)
Alabama
- Nutraceuticals Research Institute - Huntsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-10-31 |
| Est. Completion | 2025-06-30 |
| Phase | NA |
What NCT06919328 shows while recruiting
NCT06919328 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 120-participant average among 40 other Healthy Aging trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Healthy Aging appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06919328 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT06919328 about?
NCT06919328 is a clinical study titled "Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+". This study evaluates the subjective effects of injection administration of NR on healthy adult populations.
What is the current status of trial NCT06919328?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2024-10-31. Estimated completion is 2025-06-30.
What conditions does trial NCT06919328 study?
This clinical trial studies the following conditions: Healthy Aging.
What interventions are being tested in trial NCT06919328?
The interventions under investigation include: Placebo (OTHER), Niagen® (DIETARY_SUPPLEMENT), NAD+ (OTHER).
Who is sponsoring clinical trial NCT06919328?
This trial is sponsored by Nutraceuticals Research Institute, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06919328 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06919328's enrollment target sits among peer trials
70 22nd of 40 higher than 19 of 40 other Healthy Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Executive Control in Cognitively Healthy Older Adults: the MUltitasking STrategy (MUST) Study
RECRUITING · NA
-
The Mitopure Challenge to Detect Levels of Urolithin A in Dried Blood Spots
RECRUITING · NA
-
Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging
RECRUITING · NA
-
iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults
RECRUITING · NA
-
Reactive Balance Training for Fall Prevention
RECRUITING · NA
-
Neuromodulation and Fatigue
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI